<DOC>
	<DOCNO>NCT01055912</DOCNO>
	<brief_summary>The purpose study evaluate effect oral lixivaptan capsule patient congestive heart failure .</brief_summary>
	<brief_title>Study Evaluate Effects Oral Administration Lixivaptan Patients With Congestive Heart Failure</brief_title>
	<detailed_description>Diuretics use extensively treatment patient CHF , efficacy well establish . However , tendency currently use diuretic increase afterload deplete electrolyte , many patient ventricular function continue deteriorate time . Loop diuretic , furosemide , also know negative effect renal function reduce glomerular filtration rate , show activate RAA system . Lixivaptan potent , non-peptide selective antagonist vasopressin V2 receptor . Lixivaptan treatment result increase free water excretion , thus decrease urine osmolality , increase urine flow , increase serum osmolality . Short-term treatment lixivaptan demonstrate improved fluid management electrolyte balance HF patient . This study design assess effect vasopressin blockade lixivaptan patient CHF volume overload . A placebo-control arm allow assessment effect lixivaptan addition standard diuretic therapy compare standard diuretic therapy alone .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Ability understand purpose risk study provide sign date informed consent . Men woman age 18 year old . History chronic CHF define require standard HF treatment ( include diuretic ) minimum 30 day . Documented LVEF method within 12 month prior screen . The patient clinical evidence volume overload time inclusion least one following : Dyspnea Pulmonary congestion ( rale ) Peripheral edema Increased jugular venous pressure and/or hepatic congestion ascites Chest xray consistent CHF Plasma brain natriuretic peptide ( BNP ) ≥150 pg/mL Nterminal prohormone brain natriuretic peptide ( NT proBNP ) ≥450 pg/mL Women pregnant ( positive pregnancy test ) , breastfeed , adhere reproductive precaution outline protocol inform consent form ( ICF ) . Sustained ( three blood pressure measurements 1 hour ) systolic blood pressure &lt; 90 mmHg Screening Day 0 . ST segment elevation myocardial infarction stroke within 30 day prior Screening . Hemodynamically destabilizing cardiac arrhythmia within 30 day prior Day 0 . Clinically significant valvular disease . Known clinically significant obstructive , restrictive , hypertrophic cardiomyopathy . Cardiac surgery percutaneous coronary intervention within 30 day prior Day 0 . Major surgical procedure within 7 day prior Day 0 . Likely undergo cardiac transplantation , leave ventricular assist device ( LVAD ) device implantation , cardiac surgery within 3 month Screening . Placement implantable cardioverter defibrillator cardiac resynchronization therapy device within 60 day prior Day 0 . CHF due uncorrected thyroid disease , active myocarditis , know amyloid cardiomyopathy . Presence clinically significant ( determined Investigator ) endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , oncologic , and/or major disease might interfere safe compliant participation study . Screening laboratory finding follow : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal Total bilirubin &gt; 2.0 mg/dL Serum creatinine &gt; 3.0 mg/dL Hemoglobin &lt; 9.0 g/dL Uncontrolled diabetes mellitus define Investigator ( e.g. , glycosylated hemoglobin [ HbA1c ] &gt; 9 % ) . History chronic drug/medication abuse within past 6 month ; current alcohol abuse . Comorbid condition expect survival less 3 month . Known allergy vasopressin antagonist condition treatment vasopressin antagonist may present undue risk patient . Current recent administration ( within 7 day Day 0 ) prohibit medication list Section 8.6.4 . Participation investigational study drug device within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Volume Overload</keyword>
</DOC>